Marinus rises after SAGE reports postpartum depression trial results

Shares of Marinus Pharmaceuticals (MRNS), which is focused on developing and commercializing neuropsychiatric therapeutics, is higher in earlier trading after another company focused on CNS drugs, SAGE Therapeutics (SAGE), announced top-line data from an exploratory clinical trial that indicate a statistically significant improvement from baseline in depression in four women with postpartum depression. Like SAGE, Marinus’ clinical stage product candidate, ganaxolone, targets GABA receptors. In early trading, small-cap Marinus shares are up $2.16 to $11.65, while its larger peer SAGE added $10.25 to $85.40 per share.
https://bit.ly/2JO4apv